Patents Assigned to Genentech
  • Patent number: 7241862
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 26, 2001
    Date of Patent: July 10, 2007
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, Colin K. Watanabe, William I. Wood
  • Patent number: 7241865
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: July 10, 2007
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Ellen Filvaroff, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Publication number: 20070154483
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: July 5, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mass, William Novotny
  • Patent number: 7238790
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: July 3, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Jean Philippe Stephan, William I. Wood
  • Patent number: 7238658
    Abstract: Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method for identifying IGF-1 indirect agonists is provided using a detergent as a standard for the level of inhibition of binding of IGFBP-1 or IGFBP-3 to IGF-1 and/or using the coordinates of the binding pockets of IGF-1 to which a candidate indirect agonist binds for structure-based drug design.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: July 3, 2007
    Assignee: Genentech, Inc.
    Inventors: Michelle Schaffer, Mark Ultsch, Felix Vajdos
  • Patent number: 7238787
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: July 3, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
  • Publication number: 20070148177
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: June 28, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mass, William Novotny
  • Publication number: 20070148178
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: September 29, 2006
    Publication date: June 28, 2007
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert Mass, William Novotny
  • Patent number: 7235626
    Abstract: The invention is directed to a model system for structure-activity analysis of peptide or protein molecules involved in important biological processes. Provided by the invention are combinatorial peptide libraries comprising disulfide-constrained cyclic peptides with sequences favorable for energy stabilized conformations. A preferred embodiment of the invention is directed to peptides containing ?-turn tetrapeptide that form structured ?-hairpin scaffold in solution. Methods of selecting and using such peptides are provided herein, which are useful for mimicking in vivo molecular interactions and designing therapeutic agents. Thus, the invention has profound utility for biological studies and drug development.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: June 26, 2007
    Assignee: Genentech, Inc.
    Inventors: Andrea G. Cochran, Nicholas J. Skelton, Melissa A. Starovasnik
  • Patent number: 7235630
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: June 26, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
  • Patent number: 7235642
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 26, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Jean Philippe Stephan, William I. Wood
  • Patent number: 7235633
    Abstract: The present invention is directed to novel cytokine receptors having sequence similarity to AF18497_1 and to nucleic acid molecules encoding those cytokine receptors. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: June 26, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Colin K. Watanabe, William I. Wood
  • Publication number: 20070141630
    Abstract: Methods for identifying novel drug leads or binding compounds that have an affinity for a target molecule involving screening known drug fragment molecules and derivatives thereof, preferably using mass spectrometry are disclosed.
    Type: Application
    Filed: January 25, 2007
    Publication date: June 21, 2007
    Applicant: Genentech, Inc.
    Inventors: Thomas Gadek, Denise Ockey
  • Publication number: 20070141065
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: October 19, 2006
    Publication date: June 21, 2007
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev Sidhu, Christian Wiesmann
  • Publication number: 20070143871
    Abstract: The invention relates to the field of non-human, transgenic animal models for hepatocellular carcinoma.
    Type: Application
    Filed: November 6, 2006
    Publication date: June 21, 2007
    Applicant: Genentech, Inc.
    Inventors: Dorothy French, Avi Ashkenazi, Jean-Philippe Stephan, Luc Desnoyers
  • Publication number: 20070141066
    Abstract: The invention provides generally a method of monitoring, diagnosing, prognosing and treating glioma. Specifically, the invention provides for three (3) prognostic subclasses of glioma, which are differentially associated with activation of the akt and notch signaling pathways. Tumor displaying neural or proneural PN lineage markers (including notch pathway elements) show longer median patient survival, while the two remaining tumor markers Prolif and Mes are associated with shortened survival. Tumors classified in this manner may also be treated with the appropriate PN- Prolif- or Mes-therapeutic corresponding to the subclassification in combination with anti-mitotic agents, anti-angiogenic agents, Akt antagonists, and neural differentiation agents. Alternatively, the invention also provides for method of prognosing and diagnosing glioma with a two-gene model based on the expression levels of PTEN and DLL3.
    Type: Application
    Filed: December 11, 2006
    Publication date: June 21, 2007
    Applicant: Genentech, Inc.
    Inventors: Heidi Phillips, William Forrest, Samir Kharbanda, Thomas Wu
  • Publication number: 20070142284
    Abstract: The present invention provides VEGF variants having at least a single amino acid mutation in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.
    Type: Application
    Filed: September 29, 2006
    Publication date: June 21, 2007
    Applicant: Genentech, Inc.
    Inventors: Brian Cunningham, Abraham de Vos, Bing Li
  • Publication number: 20070141023
    Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
    Type: Application
    Filed: October 3, 2006
    Publication date: June 21, 2007
    Applicant: Genentech, Inc.
    Inventors: Avi Ashkenazi, Klaus Wagner
  • Patent number: 7232882
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: June 19, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood
  • Patent number: 7232889
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: June 19, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, William I. Wood